- ￥298 - 1088
- TargetMol
- USA
- T0179
- 2025年07月08日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件：
RT
- 保质期：
For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -201℃ for several months.
- 英文名：
Ticagrelor
- 库存：
详询
- 供应商：
详询
- CAS号：
274693-27-5
- 规格：
2mg/10mg/25mg/100mg/1ml/10mM
| 规格： | 2mg | 产品价格： | ￥298.0 |
|---|---|---|---|
| 规格： | 10mg | 产品价格： | ￥430.0 |
| 规格： | 25mg | 产品价格： | ￥757.0 |
| 规格： | 100mg | 产品价格： | ￥1088.0 |
| 规格： | 1ml/10mM | 产品价格： | ￥485.0 |
ID：T0179
PURITY：0.99
Formula：C23H28F2N6O4S
MolWt：522.57
Appearance：白色粉末
Solubility：G4Water： 10 μg/mL
Bioactivity：Ticagrelor (trade name Brilinta in the US, Brilique and Possia in the EU) is a platelet aggregation inhibitor produced by AstraZeneca. Unlike clopidogrel, ticagrelor is not a prodrug and does not require metabolic activation. The drug was approved for use in the European Union by the European Commission on December 3, 2010. The drug was approved by the US Food and Drug Administration on July 20, 2011.
Status：USP
Pathways：Neuroscience
Target：P2 Receptor inhibitor
Receptor：P2Y Receptor
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验]. The New England Journal of Medicine, 2014, 371(23): 2155-2166.[11]. https://www.fda.gov/downloads/Drugs/DrugSafety/UCM471586.pdf[12]. Wallentin L, Becker R C, Budaj A, et al. Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes[J
Prasugrel: A Novel Platelet ADP P2Y12 Receptor Antagonist
Novel adenosine diphosphate (ADP) P2Y12 antagonists such as prasugrel, ticagrelor, cangrelor, and elinogrel are in various phases of clinical development. These ADP P2Y12 antagonists have advantages over clopidogrel ranging from faster onset
技术资料暂无技术资料 索取技术资料
